Related to Avoiding “Incidental” Damages

• Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature
  Researchers need to step out of the gemcitabine box and also take on the development of diagnostics for early detection.
  
• Jumping On Genetic Testing—The War of the SNPs
  Molecular diagnostics still have a long way to go before they can properly deliver on all their promises.
  
• Emerging Issues in Informed Consent
  Recent lawsuits raise new questions about the subsequent use of stored genetic material.
  
• Human Genome Redux: Just a Numbers Game?
  Success of sequencing capabilities is dependent on tools to analyze the data.
  
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
  Scientists find comfort in numbers, using molecular patterns as prognostic markers.
  
• Beckman Coulter on the Chopping Block?
  Some analysts believe it is not a question of who will buy the firm but if the firm will be bought.
  
• Tumor Cells Back in Circulation for Monitoring Cancer
  With one test on the market, researchers are developing tools that leverage CTCs as biomarkers.
  
• FDA Panel Hearing Suggests Medical Professionals May Play Role in Direct-to-Consumer Testing
  Changes including more regulation may take some time, as recommendations for the agency are yet to be finalized.
  
• Do Presidential Bioethics Committees Shape Science Policy?
  Panels help frame the debate, but topics are sometimes chosen more because of political pressure than scientific need.
  
• Europe Awaits Decision on Patents, hESCs, and Morality
  Advocate General delivered opinion siding with Greenpeace, and CJEU follows the AG’s opinion 80% of the time.
  
• Diagnostic Market Stakeholders Take Aim at FDA’s RUO/IUO Draft Guidance
  Among potential changes is that manufacturers will have to anticipate customers’ intended use of their IVD products.